The ORF3 protein of hepatitis E virus delays degradation of activated growth factor receptors by interacting with CIN85 and blocking formation of the CBI-CIN85 complex by Chandra, Vivek et al.
JOURNAL OF VIROLOGY, Apr. 2010, p. 3857–3867 Vol. 84, No. 8
0022-538X/10/$12.00 doi:10.1128/JVI.01994-09
Copyright © 2010, American Society for Microbiology. All Rights Reserved.
The ORF3 Protein of Hepatitis E Virus Delays Degradation of
Activated Growth Factor Receptors by Interacting with CIN85
and Blocking Formation of the Cbl-CIN85 Complex
Vivek Chandra,1,2 Manjula Kalia,1 Krishnan Hajela,2 and Shahid Jameel1*
International Centre for Genetic Engineering and Biotechnology, New Delhi, India,1 and
School of Life Sciences, Devi Ahilya Vishwavidyalaya, Indore, India2
Received 22 September 2009/Accepted 25 January 2010
Hepatitis E virus (HEV) causes an acute self-limiting disease that is endemic in developing countries.
Previous studies suggested that the ORF3 protein (pORF3) of HEV is required for infection in vivo and is likely
to modulate the host response. Our previous work showed that pORF3 localizes to early and recycling
endosomes and causes a delay in the postinternalization trafficking of epidermal growth factor receptor
(EGFR) to late endosomes/lysosomes. Here we report that pORF3 also delays the trafficking and degradation
of activated hepatocyte growth factor receptor (c-Met) and delineate the mechanistic details of these effects. A
mutant ORF3 protein, which does not localize to endosomes, also showed similar effects on growth factor
receptor trafficking, making this effect independent of the endosomal localization of pORF3. The ORF3 protein
was found to interact with CIN85, a multidomain adaptor protein implicated in the Cbl-mediated downregu-
lation of receptor tyrosine kinases. This interaction competed with the formation of the growth factor receptor-
Cbl-CIN85 complex, resulting in the reduced ubiquitination of CIN85 and trafficking of the growth factor
receptor complex toward late endosomes/lysosomes. We propose that through its effects on growth factor
receptor trafficking, pORF3 prolongs endomembrane growth factor signaling and promotes cell survival to
contribute positively to viral replication and pathogenesis.
Hepatitis E virus (HEV) is a waterborne pathogen and the
causative agent of hepatitis E. It is transmitted feco-orally and
causes large outbreaks as well as sporadic disease (21, 37).
While this disease is endemic in developing countries of Asia,
Africa, and South America, significant levels of seropositivity
in residents of developed countries have also been observed,
which is possibly linked to the zoonotic transmission of HEV
(25, 34). It is estimated that about 2 billion people, one-third of
the world’s population, live in areas where HEV infection is
endemic (1). Although the disease is generally self-limited,
fulminant hepatitis with increased mortality has been reported
for a small fraction of patients, especially pregnant women (17,
33). Recently classified as the only member of the genus Hep-
evirus of the family Hepeviridae, HEV has a 7.2-kb capped,
polyadenylated, positive-sense RNA genome that contains
three open reading frames (ORFs). The orf1 gene encodes a
viral nonstructural polyprotein, orf2 codes for the viral capsid
protein, and orf3 encodes a small protein that is proposed to
optimize the host cell environment for viral replication (5, 6,
16, 18, 30, 31). A role for pORF3 in the release of HEV from
infected cells was also proposed recently (46). While orf3 ap-
pears to be dispensable for HEV replication in replicon-trans-
fected cells (9), it was required for the in vivo infection of
monkeys experimentally infected by the intrahepatic inocula-
tion of the viral RNA genome (10). The requirement of
pORF3 for infectivity in pigs inoculated with HEV was also
demonstrated previously (15).
The orf3 gene of HEV encodes a small protein of 123 amino
acids (aa) designated the ORF3 protein (pORF3); a recent
report proposed that pORF3 is translated from a bicistronic
subgenomic RNA and is 9 amino acids shorter at its N-termi-
nal end (11). Both forms of recombinant pORF3 show identi-
cal subcellular localizations and have similar functional effects
(5). The ORF3 protein is phosphorylated at a single serine
residue (Ser80) by the cellular extracellularly regulated kinase
(ERK), a member of the mitogen-activated protein kinase
(MAPK) family (16, 47). It contains two hydrophobic domains
in its N-terminal half and two proline-rich regions toward its
C-terminal end. Our previous studies have shown that pORF3
binds cellular proteins containing Src homology 3 (SH3) do-
mains through its proline-rich motif (18) and upregulates the
ERK/MAPK pathway by binding and inhibiting its cognate
MAPK phosphatase (16). The ORF3 protein was also found
previously to attenuate the mitochondrial death pathway (31)
and to upregulate the expression of glycolytic pathway enzymes
through the stabilization of hypoxia-inducible factor 1 (30).
Recently, we showed that pORF3 delays the movement of
activated epidermal growth factor (EGF) receptors (EGFRs)
into the degradative compartment and of the phosphorylated
signal transducer and activator of transcription 3 (pSTAT3)
protein into the nucleus (5). The former is likely to result in
extended growth factor signaling from intracellular sites, and
the latter is likely to result in an attenuation of the acute-phase
response, a major inflammatory pathway in the liver.
Growth factor receptors control a wide variety of biological
processes, including cell proliferation, differentiation, survival,
and migration (44). Ligand binding leads to receptor dimer-
* Corresponding author. Mailing address: Virology Group, Interna-
tional Centre for Genetic Engineering and Biotechnology (ICGEB),
Aruna Asaf Ali Marg, New Delhi 110 067, India. Phone: 91-11-
26742357, ext. 253. Fax: 91-11-26742316. E-mail: shahid@icgeb.res.in.
 Published ahead of print on 3 February 2010.
3857
ization and autophosphorylation, followed by the binding of
the ubiquitin ligase Cbl (41), which promotes the ubiquitin-
ation of the activated receptor at the plasma membrane and
regulates its endocytosis (12, 14, 32). In complex with the
growth factor receptor (GFR), Cbl is phosphorylated at C-
terminal tyrosine residues, resulting in a conformational
change to an open and more stable form of the PxxxPR motif.
This enhances the interaction between specific proline-argin-
ine motifs in Cbl and the SH3 domains of CIN85, a multido-
main adapter protein (20, 39). In turn, CIN85 recruits en-
dophilins to the EGFR-Cbl complexes, which regulate EGFR
endocytosis by changing the curvature of the plasma mem-
brane (4, 39). Cbl also mediates the ubiquitination of CIN85
and other molecules in the complex, which directs the recep-
tor-ligand complex for lysosomal degradation (13, 36, 45). Any
block in CIN85 binding to Cbl or its ubiquitination is known to
inhibit the degradation of the receptor (13, 39). The relatively
low affinity of CIN85 for its target proteins allows the rapid
exchange of proteins/peptides, depending on their local con-
centration and compartmentalization. Several vesicular traf-
ficking effectors interact directly with CIN85 at different steps
of endocytosis and regulate different steps of endocytic traf-
ficking (19). Thus, CIN85 acts as a master regulator and con-
trols distinct steps in the trafficking of growth factor receptors
along endocytic pathways.
The duration and strength of activated growth factor signals
are tightly regulated in the cell through various negative reg-
ulatory mechanisms. Signal termination is accomplished by
endocytosis, leading to the degradation of activated receptors.
Several viruses exploit endocytosis of growth factor receptors
for increased survival and successful replication inside the host
cell (24, 27). Previous studies showed that hepatitis viruses,
which include hepatitis B virus (HBV), hepatitis C virus
(HCV), and HEV, also modulate growth factor receptor en-
docytosis (5, 23, 26, 29). We recently showed that pORF3
localizes to early and recycling endosomes and causes a delay
in the postinternalization trafficking of EGFR (5). Here we
show that pORF3 similarly affects the hepatocyte growth factor
(HGF) receptor (HGFR) (c-Met). We further show that
pORF3 interacts with CIN85, and this interaction deregulates
the formation of the Cbl-CIN85 complex that is crucial for
growth factor receptor trafficking to the degradative compart-
ments. This study provides mechanistic details of a previously
reported observation (5).
MATERIALS AND METHODS
Plasmids, cell lines, and antibodies. The ORF3 (ORF3/4) and vector control
(pCN) stable cell lines, monoclonal antibodies to the ORF3 protein, and the
pORF3-EGFP construct and its various mutants (5, 18, 30) were all described
previously. HEV replicon plasmid pSK-E2 was a kind gift from Suzanne Emer-
son, NIH (9); the pCDNA3-FLAG-CIN85 construct was obtained from Sachiko
Kajigaya, NIH (40); and the red fluorescent protein (RFP)-tagged Rab5 con-
struct was provided by Satyajit Mayor, National Centre for Biological Sciences,
India. Antibodies to c-Met (for immunoprecipitations and flow cytometry),
EGFR, ERK1, EGFP, CIN85, ubiquitin, and phospho-tyrosine were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies to phospho-c-Met,
c-Met, and phospho-Cbl were purchased from Cell Signaling Technology (Bev-
erly, MA). Horseradish peroxidase (HRP)-conjugated secondary antibodies
were obtained from Calbiochem (San Diego, CA), while Alexa dye-conjugated
secondary antibodies were obtained from Molecular Probes (Eugene, OR).
Transfections. Transient transfections with the indicated expression vectors
were carried out with Huh7, ORF3/4, or pCN cells by using Fugene-6 reagent
(Roche, Mannheim, Germany) according to the supplier’s protocol. Cells were
typically transfected at about 50% confluence by using 2 g plasmid per 60-mm
dish. For cotransfection experiments, equal amounts of different plasmids total-
ing 3 g were used per 60-mm dish. For transfections in larger dishes, the DNA
amounts were increased proportionately.
Flow cytometry. Transfected Huh7 cells were rinsed twice with ice-cold phos-
phate-buffered saline (PBS) to remove any unbound ligand. The cells were then
chilled on ice to stop membrane trafficking, harvested, fixed using 2% parafor-
maldehyde, resuspended in PBS containing 1% bovine serum albumin (BSA),
and blocked for 45 min on ice. For total c-Met detection, the cells were perme-
abilized with 100% methanol at 20°C before blocking. The blocked cells were
labeled with anti-c-Met antibodies followed by an Alexa594-conjugated second-
ary antibody. The cells were washed with ice-cold PBS and analyzed by flow
cytometry (CyanADP; DakoCytomation, Denmark). For each sample, 10,000
cells were analyzed, and the enhanced green fluorescent protein (EGFP)-ex-
pressing cells were gated for estimating the levels of cell surface and total c-Met.
Immunoprecipitation and Western blotting. Cells were lysed with a buffer
containing 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 1% Triton X-100, and a protease inhibitor cocktail (Roche, Mannheim,
Germany). The clarified supernatant was quantified for protein concentration by
the Bradford assay (Bio-Rad Laboratories, Hercules, CA). For immunoprecipi-
tation, 1 mg of total proteins in 500 l of lysis buffer was incubated with 20 l of
protein A-agarose beads (GE Healthcare, Uppsala, Sweden) for 1 h at 4°C. The
precleared lysate was then incubated with 2 g of the antibody overnight at 4°C
followed by 20 l of protein A-agarose beads for 2 h at 4°C. After five washes in
lysis buffer, the beads were boiled in Laemmli buffer, and the proteins were
separated by SDS-PAGE. For Western blotting, proteins separated by SDS-
PAGE were transferred onto a nitrocellulose membrane (Hybond ECL; GE
Healthcare), and the membrane was blocked with Tris-buffered saline (TBS)
containing 5% Blotto (Bio-Rad, Hercules, CA) for 1 to 2 h at room temperature
(RT) and washed with TBST (TBS containing 0.1% Tween 20). The membrane
was then incubated overnight at 4°C with the primary antibody appropriately
diluted in TBST–5% BSA, washed three times for 10 min each with TBST, and
incubated with HRP-linked secondary antibodies diluted in TBST–5% Blotto for
1 h at RT. After washing as described above, chemiluminescent detection of
proteins was carried out by using the Phototope detection system (Cell Signaling
Technology, Beverly, MA) according to the supplier’s protocol.
Microscopy. To study the localization of pORF3 and its mutants, Huh7 cells
were transiently cotransfected with the appropriate expression vectors. After
48 h, the cells were fixed by using 2% paraformaldehyde for 20 min and imaged
by using a confocal microscope (Nikon A-1R). For endogenous CIN85 and HEV
replicon-expressed ORF3 staining, cells were fixed with 2% paraformaldehyde
for 20 min, permeabilized at RT with 0.4% Triton X-100 for 15 min, and stained
by using the appropriate primary and secondary antibodies.
Replicon transfection and ORF3 expression. Plasmid pSK-E2 was linearized
at a unique BglII site located immediately downstream of the HEV poly(A) tract,
and capped transcripts were synthesized as previously described (9). Transcrip-
tion mixtures were cooled on ice and then mixed with a liposome mixture
consisting of 25 l of DMRIE-C (1,2-dimyristyloxypropyl-3-dimethyl-hydroxy
ethyl ammonium bromide and cholesterol; Invitrogen, Carlsbad, CA) in 1 ml of
Opti-MEM. This mixture was added to a T25 flask containing washed S10-3 cells
at about 40% confluence. S10-3 cells are a subclone of the Huh7 cell line and
were a kind gift of Suzanne Emerson (NIH). The flasks were incubated at 34.5°C
for 6 h, an additional 1 ml of Opti-MEM was added, and incubation was con-
tinued overnight. The cells were then trypsinized, split into two T25 flasks, and
incubated in Dulbecco’s modified Eagle’s medium containing 10% fetal bovine
serum (FBS). On day 5 posttransfection, cells were again trypsinized and plated
for immunostaining, which was performed on day 8 posttransfection.
MTT assay. pCN and ORF3/4 cells were transiently transfected with either the
pcDNA3-FLAG-CIN85 expression vector or the empty vector as a control. After
48 h, the cells were washed, and 200 g/ml MTT [3-(4,5-dimethyl-2-thiazolyl)-
2,5-diphenyl-2H-tetrazolium bromide] was added for 45 min. After the removal
of the medium, dimethyl sulfoxide (DMSO) was added to each well to dissolve
the formazan crystals. The absorbance was read at 540 nm. The readings were
converted into percentage values, taking the control value as 100%.
RESULTS
ORF3-expressing cells show delayed degradation of the he-
patocyte growth factor receptor. Our previous study showed
that pORF3 delayed the degradation of the activated epider-
mal growth factor receptor (EGFR). This effect could either be
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EGFR specific or applicable to other activated growth factor
receptors as well. The hepatocyte growth factor (HGF) recep-
tor, c-Met, is relevant, as it is expressed on hepatocytes and
guides their survival and proliferation. Huh7 cells were trans-
fected to express the ORF3-EGFP fusion protein or EGFP
only as a control. At 48 h posttransfection, the steady-state
levels of surface or total c-Met were quantitated by antibody
labeling and flow cytometry of cells that were gated for EGFP
expression. While there was no change in the surface expres-
sion of c-Met, its total levels were elevated in ORF3-expressing
cells (Fig. 1A). Like EGFR, following stimulation with HGF,
c-Met is also phosphorylated, endocytosed, and eventually de-
livered to the lysosomal compartment for degradation and
signal cessation. To compare the decay kinetics of phosphory-
lated c-Met in ORF3-expressing versus control cells, the trans-
fected cells were serum starved and then stimulated with HGF
for different times, as indicated. The cells were harvested at
various times poststimulation, and the lysates were Western
blotted with anti-phospho-c-Met antibodies. In control as well
as ORF3-expressing cells, c-Met phosphorylation reached a
peak 30 min following HGF stimulation. Subsequently, the
rate of the loss of the phospho-c-Met signal was slower in
ORF3-expressing cells than in control cells (Fig. 1B). To check
the effect of delayed degradation on the total levels of EGFR
FIG. 2. The ORF3 protein also affects total growth factor receptor levels in cells. Huh7 cells were transfected with plasmid pORF3-EGFP ()
or pEGFP-N1 (). After 36 h, six sets of cells were serum starved, and two sets were kept in complete medium. Three sets of serum-starved cells
were pulsed with 100 ng/ml EGF, and the other three sets were pulsed with 50 ng/ml HGF for the indicated times. Cell lysates were prepared, and
equal amounts of total protein were Western blotted with anti-EGFR (left) or anti-c-Met (right) antibodies. Normalized lysates were also Western
blotted with anti-ERK1 and anti-EGFP antibodies for loading and expression controls, respectively.
FIG. 1. The ORF3 protein delays degradation of the activated hepatocyte growth factor receptor, c-Met. (A) Flow cytometric analysis of
surface or total c-Met in Huh7 cells transfected with either pEGFP-N1 (gray area) or pEGFP-ORF3 (black line). Single-parameter histograms are
shown for EGFP-positive cells. (B) Huh7 cells were transfected as described above and 36 h later were serum starved for 12 h. The cells were then
pulsed with 50 ng/ml HGF for the indicated times. Cell lysates containing equal amounts of total protein were Western blotted with anti-phospho-
Met antibodies. The graph on the right shows decay curves, taking the highest intensity (at 30 min post-HGF treatment) to be 100%. The gel and
decay curves are representative of three separate experiments.
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and c-Met, we transfected Huh7 cells to express either the
ORF3-EGFP fusion protein or EGFP as a control. After 36 h,
the cells were serum starved overnight and stimulated with
either EGF or HGF for different times, as indicated. One set
was also prepared without serum starvation to check for
steady-state levels, which showed higher levels of EGFR and
c-Met in ORF3-expressing cells (Fig. 2). For EGF-stimulated
cells, a clear difference in EGFR levels between ORF3-ex-
pressing and control cells was visible after 45 min of stimula-
tion; the c-Met levels were significantly different after 60 min
of HGF stimulation (Fig. 2). Together, these results show that
analogous to its effects on EGFR, the ORF3 protein delayed
the degradation of c-Met.
The endosomal localization of pORF3 is not responsible for
its effects on receptor endocytosis. The ORF3 protein contains
two hydrophobic domains (D1 and D2) in its N-terminal half
FIG. 3. The endosomal localization of pORF3 is not responsible for its effect on EGFR degradation. (A) Huh7 cells were cotransfected with
pRab5-RFP and either pORF3-EGFP or expression vectors for mutant ORF3-EGFP fusion proteins. The fixed cells were then imaged directly
for fluorescent proteins by confocal microscopy. The pORF3 and Rab5 signals were pseudocolored green and red, respectively. The merged
pictures of single confocal planes are shown. In all cases, representative images that were observed for at least 70% of coexpressing cells are shown.
(B) Huh7 cells were transfected to express EGFP or the wild-type or mutant ORF3-EGFP fusion protein in two sets. After 36 h, the cells were
serum starved for 12 h. One set was pulsed with 100 ng/ml EGF for 30 min, and another set was pulsed with 50 ng/ml HGF for 45 min. Cell lysates
containing equal amounts of total protein were immunoprecipitated (IP) with anti-EGFR (left) or anti-c-Met (right) and then Western blotted
(WB) with anti-pTyr and either anti-EGFR (left) or anti-c-Met (right) antibodies. Normalized lysates were also Western blotted with anti-ERK1
and anti-green fluorescent protein (GFP) antibodies for loading and expression controls, respectively.
3860 CHANDRA ET AL. J. VIROL.
and two proline-rich regions (P1 and P2) in its C-terminal half.
To determine which domain of the ORF3 protein is responsi-
ble for its endosomal localization, Huh7 cells were cotrans-
fected with the Rab5-RFP expression plasmid along with ex-
pression plasmids for wild-type ORF3 or its mutants in
domains D1 (deletion of aa 15 to 31), D2 (deletion of aa 37 to
62), P2 (aa 104 to 113; all Pro changed to Ala), and P1 plus P2
(deletion of aa 74 to 123). The cells were then imaged by
confocal microscopy. Except for D1-deleted ORF3 (D1-
ORF3), all other mutants showed a punctate distribution and
colocalization with Rab5, a marker of early endosomes (Fig.
3A). The D1-ORF3 mutant, however, was distributed evenly
in the cell and showed no colocalization with Rab5 (Fig. 3A2).
This clearly demonstrated that hydrophobic domain 1 (D1) of
the ORF3 protein is responsible for its endosomal localization.
We then tested whether the endosomal localization of pORF3
was responsible for its effect on EGFR phosphorylation, a
modification that marks the activated receptor for degradation.
Huh7 cells were transfected to express either wild-type ORF3-
EGFP, mutant ORF3-EGFP fusion proteins, or EGFP only as
a control. At 36 h posttransfection, cells were serum starved
overnight and then stimulated with either EGF for 30 min or
HGF for 45 min. The cells were harvested, and the lysates were
immunoprecipitated with anti-EGFR or anti-Met antibodies
followed by Western blotting with anti-pTyr antibodies. There
was a consistent increase in phospho-EGFR and phospho-c-
Met levels in cells expressing either the wild-type or mutant
ORF3 proteins compared to control cells expressing only
FIG. 4. The ORF3 protein interacts with CIN85. (A) Huh7 cells were transfected to express EGFP (control) or the ORF3-EGFP or
D1-ORF3-EGFP fusion protein. After 48 h, cell lysates were prepared and immunoprecipitated with either anti-EGFP or anti-CIN85 antibodies,
followed by Western blotting with anti-CIN85 or anti-EGFP antibodies, respectively. Normalized lysates were also Western blotted with anti-EGFP
and anti-CIN85 antibodies, which served as expression controls for the expressed proteins. (B) Huh7 cells were cotransfected with pcDNA3-
FLAG-CIN85 and either pEGFP-N1 (control) or pORF3-EGFP. After 48 h, cell lysates were prepared, and equal amounts of total protein were
immunoprecipitated with anti-GFP, followed by Western blotting with anti-FLAG antibodies. Cell lysates were also Western blotted with
anti-FLAG and anti-GFP antibodies to serve as expression controls. (C) Huh7 cells were transfected with the pORF3-EGFP expression vector (1),
or S10-3 cells were transfected with in vitro-synthesized capped replicon transcript (2), as described in Materials and Methods. The cells were fixed
and stained for CIN85 using a rabbit anti-CIN85 antibody and for pORF3 with a monoclonal anti-ORF3 antibody (2). The stained cells were
imaged by confocal microscopy. The pORF3 and CIN85 signals were pseudocolored green and red, respectively. The merged pictures of single
confocal planes are shown. Details are also shown for the boxed regions. In all cases, representative images that were observed for at least 70%
of coexpressing cells are shown.
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EGFP (Fig. 3B). Compared to wild-type pORF3, its hydropho-
bic domain mutants D1 and D2 showed no decrease, while
the proline-rich-region mutants P2 and P1P2 showed20%
and 50 to 60% reductions, respectively, in phospho-EGFR
and phospho-c-Met levels. However, none of these mutants
totally abrogated the stabilizing effects of pORF3 on activated
growth factor receptors. Thus, while the D1-ORF3 protein
does not localize to early endosomes like the wild-type ORF3
protein, it shows similar effects on GFR phosphorylation. Al-
ternatively, the P2-ORF3 and P1P2-ORF3 proteins localize
to early endosomes but show reduced phospho-GFR levels.
This finding supports the idea that the localization of pORF3
to endosomes is not responsible for its effect on GFR traffick-
ing, and this function is probably linked to the proline-rich
regions of pORF3.
The ORF3 protein interacts with CIN85, a regulator of
growth factor receptor endocytosis. The CIN85 protein is a
major regulator of growth factor receptor endocytosis, which
functions by binding Cbl and several other adapter proteins
(19, 35, 39, 40). The ubiquitination of activated growth factor
receptors and CIN85 by Cbl directs the complex for lysosomal
degradation. Since the Cbl-CIN85 interaction is through pro-
line-rich regions in the former and SH3 domains in the latter,
and since pORF3 contains proline-rich regions, one of which
was previously shown to bind SH3 domains (18), we wondered
if pORF3 functions by binding CIN85 and competing it away
from the Cbl-CIN85 complex. To test for a direct interaction
between pORF3 and CIN85, we transfected Huh7 cells to
express either the ORF3-EGFP or the D1-ORF3-EGFP fu-
sion protein using pEGFP as a control. The cell lysates were
immunoprecipitated with anti-EGFP or anti-CIN85 antibodies
followed by Western blotting with anti-CIN85 or anti-EGFP
antibodies, respectively. As shown in Fig. 4A, anti-EGFP anti-
bodies precipitated endogenous CIN85 from Huh7 cells express-
ing the ORF3-EGFP or D1-ORF3-EGFP fusion protein but
not from cells expressing EGFP. Similarly, anti-CIN85 antibodies
precipitated the ORF3-EGFP or D1-ORF3-EGFP fusion pro-
tein but not EGFP (Fig. 4A), confirming the specific interaction
between these proteins. We also carried out a coimmunopre-
cipitation assay using lysates from Huh7 cells cotransfected
with vectors expressing wild-type or mutant ORF3-EGFP fu-
sions and an expression vector for FLAG-tagged CIN85. As
described above, cell lysates were immunoprecipitated with
anti-EGFP antibodies and then Western blotted with anti-
FLAG antibodies. The results presented in Fig. 4B show that
FLAG-tagged CIN85 was pulled down from cells expressing
wild-type or mutant pORF3 but not from control cells. As
described above, this showed that the hydrophobic domains
(D1 and D2) of the ORF3 protein were not required for its
binding to CIN85. It further showed that sequences outside the
proline-rich domains (P1 and P2) may also be involved in the
binding of pORF3 to CIN85. We also checked the localization
of pORF3 and CIN85 in Huh7 cells and found that the two
proteins colocalize (Fig. 4C). Whether the ORF3-EGFP fusion
protein was expressed from a plasmid vector (Fig. 4C1) or the
native ORF3 protein was expressed from the transfected HEV
FIG. 5. Overexpression of CIN85 reverses the effect of pORF3 on growth factor endocytosis and cell survival. Control and ORF3-expressing
stable cell lines were transfected with different amounts of the pcDNA3-FLAG-CIN85 expression vector as indicated and a vector control to keep
the total amount of plasmid constant. After 36 h, cells were serum starved overnight and then pulsed with either 100 ng/ml EGF for 30 min or 50
ng/ml HGF for 45 min. Cell lysates were prepared, and equal amounts of total protein were immunoprecipitated by using anti-EGFR (left) or
anti-Met (right) and then Western blotted with anti-pTyr and anti-EGFR or anti-Met antibodies, as shown. Normalized lysates were also Western
blotted with anti-FLAG and anti-ERK1 antibodies for CIN85 expression and loading controls, respectively. (B) pCN and ORF3/4 cells were
transiently transfected with the pcDNA3-FLAG-CIN85 expression vector and control empty vector. After 48 h, the cells were washed, and an MTT
assay was carried out as described in Materials and Methods. The readings were converted into percent survival, taking the control as 100%.
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replicon (Fig. 4C2), the proteins showed significant overlap
with endogenous CIN85 in Huh7 cells. Together, these results
confirm that pORF3 interacts directly with CIN85.
Overexpression of CIN85 reverses the effects of pORF3 on
growth factor receptors and cell survival. Since pORF3 inter-
acts directly with CIN85, this interaction might be responsible
for delayed receptor degradation in ORF3-expressing cells. To
test this directly, we took cells that stably expressed pORF3
(ORF3/4 cells) and controls (pCN cells) and transfected dif-
ferent subsets with 0, 1, 2, and 3 g of the pcDNA3-FLAG-
CIN85 expression vector. After 36 h, the cells were stimulated
with either EGF for 30 min or HGF for 45 min and harvested,
and the lysates were immunoprecipitated with anti-EGFR or
anti-c-Met antibodies, followed by Western blotting with anti-
pTyr antibodies. The steady-state levels of phosphorylated (ac-
tivated) EGFR or c-Met were higher in ORF3-expressing cells
than in control cells (Fig. 5A). However, when CIN85 was
overexpressed in these cells, the stabilizing effects of pORF3
on activated EGFR and c-Met were progressively lost in cells
transfected with 1 or 2 g of the pcDNA3-FLAG-CIN85 ex-
pression vector (Fig. 5A), while transfection with 3 g of the
pcDNA3-FLAG-CIN85 expression vector resulted in severe
cell death in the ORF3-expressing cells (not shown). These
results support our hypothesis that the direct interaction of
pORF3 and CIN85 is responsible for the former’s effects on
growth factor receptors. Since the overexpression of CIN85 is
likely to reverse the effects of pORF3 on growth factor signal-
ing, we checked the effects of pORF3 on cell survival in the
presence and absence of CIN85. We took the stable cell lines
ORF3/4 and pCN (as a control) and transfected one subset
with 2 g of the pcDNA3-FLAG-CIN85 expression vector and
the other with an empty control vector. Another set of ORF3/4
cells was cotransfected with 2 g each of pcDNA3-FLAG-
CIN85 and pORF3-EGFP. After 48 h, cell viability was eval-
uated by using a colorimetric assay based on MTT staining.
The ORF3/4 cells that also expressed CIN85 showed about
50% cell death, but when more ORF3 was transiently ex-
pressed in these cells, there was only about 20% cell death
(Fig. 5B). These results suggest that the effects of pORF3 on
the growth factor pathway are also responsible for its prosur-
vival effects on cells.
The ORF3 protein blocks formation of the Cbl-CIN85 com-
plex. The ORF3 protein is likely to attenuate growth factor
receptor (GFR) degradation by interacting with CIN85 in two
possible ways. It could trap the GFR-Cbl-CIN85 complex in
early or recycling endosomes by delaying its trafficking to the
late endosomal/lysosomal compartment, or it could interfere
with the formation of the Cbl-CIN85 complex. To test this, we
transfected Huh7 cells to express either the ORF3-EGFP fu-
sion protein or EGFP as a control. After 36 h, the cells were
serum starved overnight and then stimulated with either EGF
or HGF for 30 min or 45 min, respectively. One set of trans-
fected cells was left without serum starvation to assess steady-
state levels. The lysates were immunoprecipitated with anti-
FIG. 6. The ORF3 protein reduces formation of the growth factor receptor-Cbl-CIN85 complex. (A) Huh7 cells were transfected with plasmid
pORF3-EGFP () or pEGFP-N1 (). After 36 h, two sets of cells were serum starved, and one set was kept in complete medium. One set of
serum-starved cells was pulsed with 100 ng/ml EGF for 30 min, and the other was pulsed with 50 ng/ml HGF for 45 min. Cell lysates were prepared,
and equal amounts of total protein were immunoprecipitated with anti-CIN85 antibodies followed by Western blotting with anti-pCbl, anti-EGFP,
or anti-CIN85 antibodies. Normalized lysates were also Western blotted with anti-ERK1 and anti-EGFP antibodies as loading and expression
controls, respectively. (B) The anti-CIN85 immunoprecipitates from A were Western blotted with anti-EGFR antibodies (for EGF-stimulated
lysates) or anti-c-Met antibodies (for HGF-stimulated lysates). The immunoprecipitates from non-serum-starved cells (steady state) were Western
blotted with both antibodies. Immunoprecipitates were also Western blotted with anti-CIN85 antibodies.
VOL. 84, 2010 HEV ORF3 PROTEIN BLOCKS Cbl-CIN85 COMPLEX FORMATION 3863
CIN85 antibodies, followed by Western blotting with anti-
phospho-Cbl antibodies. In ORF3-expressing cells stimulated
with either EGF or HGF, or cells kept in serum-containing
medium, there was a reduced level of binding of CIN85 with
phospho-Cbl (Fig. 6A). Upon densitometric quantitation, this
reduction was60 to 75% in ORF3-expressing cells compared
to control cells, suggesting that pORF3 interferes with the
formation of the Cbl-CIN85 complex. We also used the same
anti-CIN85 immunoprecipitated lysate to assess the levels of
growth factor receptors in the CIN85 complex. As expected,
reduced levels of EGFR and c-Met were observed in associa-
tion with CIN85 (Fig. 6B). These results confirm that pORF3
competes with Cbl to form a complex with CIN85 and that this
competition leads to reduced levels of the growth factor re-
ceptors in the GFR-Cbl-CIN85 complex; the latter is essential
for the endocytosis and trafficking of activated GFRs to the
degradative compartment.
Reduced ubiquitination of CIN85 in ORF3-expressing cells.
The Cbl-induced ubiquitination of growth factor receptors
takes place at the plasma membrane and provides the initial
signal for receptor endocytosis. Cbl also remains associated
with the ligand-bound EGFR in early and late endosomes. In
addition to activated receptors, receptor-associated proteins
like CIN85 are also ubiquitinated by Cbl, which acts as a gating
receptor for ubiquitinated cargo, thus amplifying the ubiquitin
network. Any block in CIN85 ubiquitination leads to a reduced
degradation of the activated receptor. Our results thus far
show that pORF3 interacts with CIN85 and competes with the
formation of the Cbl-CIN85 complex. It is thus expected that
pORF3 will also result in a reduced ubiquitination of CIN85.
To test this, Huh7 cells were transfected to express either the
ORF3-EGFP fusion protein or EGFP as a control. After 36 h,
the cells were serum starved overnight and stimulated with
either EGF or HGF for 30 or 45 min, respectively. One set was
also prepared without serum starvation to check for equilib-
rium levels. The cell lysates were immunoprecipitated with
anti-CIN85 antibodies and then Western blotted with anti-
ubiquitin antibodies. Following stimulation with either EGF or
HGF, there was a ubiquitination of CIN85, which was signifi-
cantly lower in cells expressing the ORF3 protein. Compared
to controls, we observed about 10% or 60% CIN85 ubiquitin-
ation in ORF3-expressing cells stimulated with EGF or HGF,
respectively (Fig. 7A). Similarly, ORF3-expressing cells not
starved of serum (steady state) also showed about 50% CIN85
ubiquitination compared to control cells (Fig. 7A). This was
also observed for the steady state, where cells were neither
starved of serum nor subsequently stimulated with the growth
factors. There was no change in the total levels of the CIN85
protein between ORF3-expressing and control cells. Growth
factor receptors are ubiquitinated by the Cbl ubiquitin ligase
after binding to it. To check for any effect of pORF3 on the
ubiquitination of EGFR and c-Met, we transfected Huh7 cells
to express either the ORF3-EGFP fusion protein or EGFP as
a control. After 36 h, the cells were serum starved overnight
and stimulated with either EGF or HGF for 30 or 45 min,
respectively. The cell lysates were immunoprecipitated with
anti-EGFR and anti-c-Met antibodies and then Western blot-
ted with anti-ubiquitin antibodies. As expected, we did not find
any significant change in the ubiquitination of EGFR and
c-Met in ORF3-expressing cells (Fig. 7B).
DISCUSSION
The controlled processing of information is critically impor-
tant for the existence and development of biological systems.
The loss of synchrony and interplay of signals between com-
ponents of signaling networks, which are caused by several
pathogens, contribute to their pathogenesis. Viruses are small
and contain limited genetic information, making it imperative
that viral proteins to be multifunctional.
HEV is a small virus that causes an acute self-limiting in-
fection, even in the face of a robust antiviral immune response
(7, 42). Previous studies carried out by us and others have
shown that the HEV ORF3 protein regulates cellular pro-
cesses and has three broad roles. The first role is the promotion
of cell survival through the activation of the ERK/MAPK sig-
naling pathway (16), attenuation of the intrinsic death pathway
(31), regulation of energy homeostasis (30), and increased
growth factor signaling, possibly from endomembrane sites (5).
The second role is the downregulation of host immune re-
sponses through the reduced expression of acute-phase pro-
FIG. 7. The ORF3 protein reduces ubiquitination of CIN85. Huh7
cells were transfected with plasmid pORF3-EGFP () or pEGFPN1
() and treated as described in the legend of Fig. 5. Cell lysates
containing equal amounts of total protein were immunoprecipitated
with anti-CIN85 antibodies and then Western blotted with anti-ubiq-
uitin (Ub) or anti-CIN85 antibodies. Normalized lysates were also
Western blotted with anti-ERK1 and anti-GFP antibodies for loading
and expression controls, respectively. Huh7 cells were transfected with
plasmid pORF3-EGFP () or pEGFP-N1 (). After 36 h, cells were
serum starved and were pulsed with either 100 ng/ml EGF for 30 min
or 50 ng/ml HGF for 45 min. Cell lysates were prepared, and equal
amounts of total protein were immunoprecipitated with anti-EGFR
(left) or anti-c-Met (right) antibodies followed by Western blotting
with anti-ubiquitin and either anti-EGFR or anti-c-Met antibodies.
Normalized lysates were also Western blotted with anti-ERK1 and
anti-GFP antibodies for loading and expression controls, respectively.
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teins (5) and increased secretion of the immunosuppressive
1-microglobulin protein (43). Recent studies have also sug-
gested the requirement of pORF3 for virion morphogenesis
and its release from infected cells (46). Thus, pORF3 appears
to be a multitasking regulatory protein that helps in the estab-
lishment, propagation, and progression of HEV infection. In-
deed, the ORF3 protein was required for viral infection fol-
lowing the intrahepatic inoculation of HEV genomic RNA
directly into monkey liver (10) or pigs (15) but was dispensable
for the propagation of a viral replicon in transfected cells in
vitro (9).
Endocytosis is essential for the entry and productive infec-
tion of several viruses. Many viruses have also been found to
incorporate components of the endocytic machinery in their
survival and replication strategies (24, 27). We recently ob-
served that pORF3 localizes to early and recycling endosomes
and modulates the intracellular trafficking of activated EGFR
(5). In the present study, we found pORF3 to have similar
effects on c-Met, the cellular receptor for hepatocyte growth
factor, which is critical for the survival and proliferation of
hepatocytes (2, 3, 28, 38). These cells are believed to be the
primary site of HEV infection and replication. A recent report
demonstrated similar effects of the hepatitis C virus (HCV)
NS5A protein on EGFR endocytosis (23). Hepatitis B virus
(HBV) was also shown previously to activate growth factor
receptor expression (26). Thus, this appears to be a general
mechanism that may be utilized by hepatotropic viruses to
promote the survival of infected cells, which would be required
for efficient viral replication.
We also address the molecular mechanism responsible for
the effects of pORF3 on growth factor receptors. An ORF3
protein deleted of its N-terminal hydrophobic domain 1 (D1)
did not localize to early endosomes but still showed increased
steady-state levels of phosphorylated EGFR and c-Met, which
is indicative of its reduced degradation. This suggested that the
endosomal localization of pORF3 was not required for its
effect on growth factor receptor endocytosis and trafficking.
Our earlier work showed that the ORF3 protein does not alter
the endocytic trafficking of either the fluid phase or transferrin
receptor but affects only the trafficking of EGFR (5).
The trafficking of growth factor receptors is regulated by a
complex network of protein-protein and protein-lipid interac-
tions as well as by protein posttranslational modifications, such
as phosphorylation and ubiquitination. The ligand-induced
ubiquitination of growth factor receptors has been linked to
their internalization and endocytosis (14). The Cbl family of
ubiquitin ligases plays pivotal roles in these processes. The Cbl
protein can bind directly to phosphorylated growth factor re-
ceptors via its tyrosine kinase-binding (TKB) domain, while its
RING finger domain recruits ubiquitin-conjugating enzymes
(e.g., E2 and Ubc) and mediates the transfer of ubiquitin to
activated receptors (8). Cbl also recruits several endocytic reg-
ulatory proteins, including CIN85-endophilin complexes, to
the activated growth factor receptors (8, 35). The binding of
CIN85 to Cbl is enhanced by the growth factor-induced ty-
rosine phosphorylation of Cbl that leads to a conformational
change in the distal carboxyl termini of Cbl (20, 39). The
proline-rich region of CIN85 also constitutively associates with
endophilins, recruiting the Cbl-growth factor receptor com-
plexes to clathrin-coated vesicles. CIN85 and several other
proteins in the complex are also ubiquitinated by Cbl upon
growth factor stimulation, which is required to direct the re-
FIG. 8. Model for ORF3 protein-mediated regulation of growth factor receptor endocytosis. Following its ligation by growth factor (GF), the
growth factor receptor (GFR) is phosphorylated at Tyr residues in its cytoplasmic domain. The pTyr residues bind Cbl, which in turn binds the
multidomain adaptor protein CIN85 through proline-arginine-rich sequences in Cbl and the SH3 domains in CIN85. The CIN85 protein separately
binds endophilin, which recruits the GFR-Cbl-CIN85 complex to clathrin-coated vesicles. The RING finger domain of Cbl recruits ubiquitin-
conjugating enzymes and ubiquitinates GFR as well as CIN85, which regulates GFR trafficking toward late endosomes/lysosomes. The ORF3
protein binds CIN85, directly competes with the binding of Cbl to CIN85, and leads to a reduced ubiquitination of CIN85. This delays the
trafficking of GFR to the degradative compartments.
VOL. 84, 2010 HEV ORF3 PROTEIN BLOCKS Cbl-CIN85 COMPLEX FORMATION 3865
ceptor-ligand complex for degradation (13, 36, 45). Several
vesicular trafficking effectors interact directly with CIN85 at
different steps of endocytosis (19). Thus, CIN85 acts as a mo-
lecular scaffold and controls distinct steps in the endocytic
trafficking of growth factor receptors.
Some viruses such as herpes simplex virus (HSV) modulate
growth factor endocytosis by regulating the formation of the
Cbl-CIN85 complex. HSV protein 0 forms a complex with
CIN85 and Cbl and mediates the ligand-independent degrada-
tion of EGFR from the cell surface; this precludes signaling to
the infected cells through receptor tyrosine kinases (22). The
CIN85 protein binds Cbl through SH3 domains in the former
and proline-arginine-rich motifs in the latter (18). The HEV
ORF3 protein is also proline rich and was shown previously to
bind many SH3 domain-containing proteins (18). Here we show
that pORF3 interacts directly with CIN85 and competes with the
Cbl-growth factor receptor complex for its binding. The C-termi-
nal amino acid sequence of pORF3, 117PQLGPR122, is an exact
match to the consensus Cbl sequence that binds the CIN85 SH3
domain (20). Following the deletion of this sequence, the P1P2
mutant still showed residual binding (Fig. 4B). This could be due
either to the overexpression of pORF3 or to the presence of
other proline-rich motifs in pORF3 outside the P1 and P2
regions and a rather plastic SH3 binding motif in CIN85 (20).
In support of the pORF3-CIN85 interaction, we also found
pORF3, either overexpressed from a plasmid vector or ex-
pressed from the HEV replicon, to colocalize with CIN85. By
competing with Cbl for binding to CIN85, the ORF3 protein
also reduces the ubiquitination of CIN85 as well as its postin-
ternalization interaction with other molecules, which are re-
quired for the lysosomal degradation of the receptor. These
events lead to the prolonged intracellular survival of activated
growth factor receptors as also endomembrane survival signal-
ing in ORF3-expressing cells. This is likely to create a favor-
able environment for viral replication.
Collectively, our data provide a novel example of a viral
protein that blocks growth factor receptor degradation by in-
teracting with the multidomain adapter protein CIN85. A
mechanistic model for this also emerges from our study. The
ORF3 protein interacts with CIN85 and competes with the
formation of the growth factor receptor-Cbl-CIN85 complex
following growth factor activation. This reduced complex for-
mation results in a reduced ubiquitination of CIN85, which
results in a delayed degradation of activated receptors (Fig. 8).
These effects would promote the survival of infected cells and
are likely to aid in the replication and pathogenesis of these
small hepatotropic viruses.
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